ArticleThe Journal of veterinary medical science2019
Phillyrin is an effective inhibitor of quorum sensing with potential as an anti-Pseudomonas aeruginosa infection therapy.
Article in The Journal of veterinary medical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Phillyrin Alleviates Memory Impairment in D-Galactose-Induced Aged Mice by Suppressing Hippocampal Neuroinflammation via the TLR4/NF-κB Signaling Pathway.Food science & nutrition · 2026Article
- Comparative inhibitory effects of phillyrin and phillygenin on elastase: mechanisms and therapeutic potential.Frontiers in nutrition · 2026Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
- Renal Biomarkers in Companion Animals-A Review.Animals : an open access journal from MDPI · 2025Review
- Impact of Antimicrobial Resistance ofVeterinary sciences · 2025Review
- Study on the Effect of Phillyrin onBiomolecules · 2024Article
- Unveiling the hidden language of bacteria: anti-quorum sensing strategies for gram-negative bacteria infection control.Archives of microbiology · 2024Review
- Review on the Pharmacological Properties of Phillyrin.Molecules (Basel, Switzerland) · 2022Review
- Effects of active compounds fromRSC advances · 2022Article
- Gregatins, a Group of Related Fungal Secondary Metabolites, Inhibit Aspects of Quorum Sensing in Gram-Negative Bacteria.Frontiers in microbiology · 2022Article
- Prediction of the Active Components and Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- 6-Methylcoumarin attenuates quorum sensing and biofilm formation in Pseudomonas aeruginosa PAO1 and its applications on solid surface coatings with polyurethane.Applied microbiology and biotechnology · 2021Article
- The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.Pharmacological research · 2020Review
- Quorum Quenching: A Potential Target for Antipseudomonal Therapy.Infection and drug resistance · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we evaluated the antibacterial and anti-quorum sensing qualities of phillyrin. The minimum inhibitory concentration (MIC) of phillyrin with regard to Pseudomonas aeruginosa is 0.5 mg/ml. The production of virulence factors-such as rhamnolipid (>78.69%), pyocyanin (>85.94%), and elastase (>89.95%)-that affect the pathogenicity of the P. aeruginosa strain PAO1 apparently declined in the presence of 0.25 mg/ml phillyrin. Biofilm formation decreased by 84.48%. In a Caenorhabditis elegans-Pseudomonas aeruginosa infection model, diseased worms lived longer (63.33%) in a phillyrin-containing medium than in a drug-free medium, and the drug did not directly kill the pathogen. Therefore, the present work suggests that phillyrin has potential as an antimicrobial agent for the control of infectious pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.